Compare Heron Therapeutics Inc (HRTX) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Charles Schwab Corporation Common Stock — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while Charles Schwab Corporation Common Stock trades at $100.77 (market cap $178.33B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 1949.8× Heron Therapeutics Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.25% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | SCHW | |
|---|---|---|
Market Cap | $91.46M | $178.33B |
Sector | Health | Financials |
52-Week High | $1.96 | $107.21 |
52-Week Low | $0.39 | $85.35 |
Enterprise Value | $189.36M | — |
Dividend Yield | — | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Charles Schwab (SCHW) trades at $102.01, up 0.44% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $1.43 and revenue growth accelerating to $23.92 billion in 2025. Analyst sentiment remains positive with 58% buy ratings and a $120 consensus price target representing 18% upside potential. Recent news highlights strong trading activity and earnings optimism ahead of Q2 results.
The outlook remains favorable with earnings momentum and operational strength driving potential upside. Key opportunities include continued trading revenue growth and margin expansion, while risks involve interest rate sensitivity and market volatility. The stock's current valuation at 20.19 P/E appears reasonable given the company's profitability and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
